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HistopathologyAbstract Objective: The purpose of this study was to investigate the correlation between the FDG
PET CT and histopathology in grading of gliomas.
Methods: 16 patients with clinically diagnosed glioma performed dual phase FDG PET CT of the
brain for staging, and the staging was correlated to the histopathological classiﬁcation in the sur-
gical specimen.
Results: We found good correlation between the dual phase PET CT grading and the histopatho-
logical grading of gliomas, when a 23% increase was used as the cutoff for analysis of the difference
in SUVmax of the lesion (L) versus normal gray matter (GM) over time, the sensitivity was 88.9%,
the speciﬁcity was 85.7%, and the accuracy was 89.4% (P= 0.003; AUC= 0.94).
Conclusion: Dual phase FDG PET CT is a reliable predictor of proliferative activity of gliomas
and could be used as a method of grading of the tumor.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Preoperative assessment of tumor proliferative activity or
malignancy has a potentially signiﬁcant impact on the thera-
peutic strategy for patients with brain tumor. Positron emis-
sion tomography has been the method of choice for
evaluating metabolism and malignancy (1).The World Health Organization (WHO) classiﬁcation of
tumors of the central nervous system is a representative classi-
ﬁcation system for grading of a brain tumor, and is accepted
and used worldwide (2).
Grading is based on the degree of nuclear atypia, mitosis,
microvascular proliferation, and necrosis, with increasing ana-
plasia as tumor grade increases. The histologic features of the
tumor and the age and performance status of the patient are
major prognostic factors on outcome (3). Furthermore, PET
has been introduced as an important tool in the deﬁnition of
the tumor extent for therapy planning (4).
Dual-time-point 18F-FDG PET has signiﬁcantly improved
the diagnostic sensitivity and speciﬁcity for head and neck can-
cers, breast cancer, malignant lung lesions, and some others
(5). Spence et al. (6) have introduced this methodology in
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quantitatively using volumes of interest (VOIs). They investi-
gated the behavior of model-derived kinetic rate constants
over time and concluded that 18F-FDG is dephosphorylated
faster from normal tissue than from tumor, improving image
contrast.
In this study, we correlated the results of the FDG PET CT
of the brain glioma with the histopathological classiﬁcation of
the tumor specimen obtained at surgery.
2. Patients and methods
2.1. Study population
Sixteen patients with glioma, 9 men and 7 women, 24 to
60 years old (mean age, 40 years), were examined in the study
during the period of July 2014 to March 2015. All patients per-
formed dual phase FDG PET CT in a private center and sub-
sequent surgery for subtotal or total tumor removal. The PET
CT study was performed within 2 weeks prior to surgery. The
results were correlated to the histological classiﬁcation in all
patients.
2.2. Dual phase PET CT protocol
Patients fasted for at least 8 h before F-18 FDG positron emis-
sion tomography with computed tomography (PET/CT).
Mean fasting serum glucose of patients was 118–150 mg/dL,
and 4 patients had a history of diabetes mellitus. The early
PET/CT scans were started 40 to 45 min after the administra-
tion of 8–15 mCi F-18 FDG using an hybrid PET/CT system
(Ingenuity, TF PET/CT /Philips, the Netherlands), and the
delayed PET/CT scans were performed at 75 min after the
early scan. The axes of both systems are mechanically aligned
to coincide optimally. CT data were acquired ﬁrst and the fol-
lowing parameters were used: tube rotation time, 0.5 s perFig. 1 50 years old patient with left frontal low grade glioma by no
SUVmax of the lesion = 6 and 4.7 in the late scan, difference of 2
difference of about 24.4%, and the ratio between the lesion and gray
L/GM difference of 3.6%.revolution; 120 kV; 140 mAs; reconstructed slice thickness,
5 mm. No contrast medium was used for the CT examination.
After the acquisition of CT data had been completed, the
tabletop with the patient automatically advanced into the
PET sensitive ﬁeld of view and acquisition of PET data was
started in
3-dimensional mode with the patient in exactly the same posi-
tion on the table. Scanning was performed in one bed position
for 3 min. The attenuation correction was automatically
completed using corresponding CT data.
2.3. Data analysis
Semi-quantitative analysis of PET images was performed, and
Maximum and mean standardized uptake values (SUVmax
and SUVmean) of the lesion and normal gray matter were
measured at early (1) and delayed (2)) imaging sessions.
Circular regions of interest (0.5–1.0 cm, as appropriate) were
used to determine the mean and max SUV of the lesion (L),
and of the normal contralateral frontal gray matter (GM) at
the level of the thalamus and the centrum semiovale (WM).
Ratios of L SUVmax to GM SUVmax at early and late
time points (L1/GM1 and L2/GM2 respectively) were
calculated individually, and the change between early and
late L to GM ratios was calculated using the formula:
[(L2/GM2  L1/GM1)/(L1/GM1)]. Similar calculations were
performed using GM SUVmean, WM SUVmean and WM
SUVmax (Fig. 1).
2.4. Statistical analysis
The diagnostic accuracy of PET derived indices was calculated
usingReceiver Operating Curve (ROC) analysis. The cutoff val-
ues were determined automatically by the ROC analysis pro-
gram. The optimal cutoff value for these variables was deﬁned
as the point on the ROC curve with minimal distance fromncontrast CT (a), early (b) and late (c) PET images showed, early
1.7%, the GM early SUVmax was 7.8 and 5.9 in the late scan,
matter uptake was 0.77 in the early and 0.80 in the late phase with
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rate and 0% false-negative rate). The area under the ROC curve
(AUC) was determined with its corresponding 95% conﬁdence
interval. The cutoff values obtained were further tested to deter-
mine the sensitivity, speciﬁcity, and accuracy. P< 0.05 was
used to deﬁne statistical signiﬁcance.
3. Results
Dual phase FDG-PET/CT imaging was performed on 16 con-
secutive patients 9 men and 7 women, 24–60 years old (mean
age, 40 years). Based on histopathological data of the 16
patients included in our study, 7 patients had low grade glio-
mas while 9 had high grade gliomas. All patients did not
receive chemotherapy or radiotherapy at the time of
examination.
Table 1 shows SUVmax early and SUVmax late of the
lesions (L) and gray matter (GM), as well as the percent
change over time, and ratios of L SUVmax to GM SUVmax
at early and late time points, and the percent change in
L/GM over time as well as the corresponding PET CT and
histopathological grading. SUVmean data trends (not shown)
were similar to SUVmax trends, but the latter were more accu-
rate at predicting the diagnosis. The most accurate parameter
of all variables analyzed, the ratio of the change of the lesion to
GM ratios over time [(L2/GM2  L1/GM1)/(L1/GM1)] was
the most sensitive and speciﬁc predictor of outcome. When a
23% increase was used as the cutoff for analysis of the differ-
ence in SUVmax of the lesion (L) versus normal gray matter
(GM) over time, the sensitivity was 88.9%, the speciﬁcity
was 85.7%, and the accuracy was 89.4% (P= 0.003;
AUC= 0.94). Other parameters such as the mean SUV, early
SUV ratios, and SUV at early or late time points were less
accurate. The change in SUVmax of lesion to gray matter over
time was clearly the most accurate parameter. In some cases,
delayed images demonstrated tumor activity much more con-
vincingly than the early images did. This was most notableTable 1 Results of SUVmax of lesion (L) and normal GM (GM)
difference over time of all patients and their corresponding PET CT
Patient L SUVmax Diﬀerence in
Lesion SUVmax
(%)
GM
SUVmax
Diﬀerence in
SUVmax (%
Early Late Early Late
1 3.5 3.4 2.9 2.9 2.3 20.7
2 10 10.2 2.0 11 11.4 3.6
3 16.8 22.8 35.7 8.1 6.5 19.8
4 5.9 6.5 10.2 10.5 9.6 8.6
5 6 4.7 21.7 7.8 5.9 24.4
6 12 13.7 14.2 8.6 5.2 39.5
7 2.3 2.1 8.7 5.1 4.1 19.6
8 8.7 9.9 13.8 10.6 7.4 30.2
9 6.5 6.8 4.6 7.5 6.6 12
10 2.2 2.7 22.7 1.7 1.3 23.
11 14.2 15 5.6 6.5 4.3 33.8
12 19.1 21.2 11.0 8.3 6.4 22.9
13 9 8.7 3.3 8.9 6.6 25.8
14 3.2 3.1 3.1 4.9 4.5 8.2
15 5.9 6.2 5.1 8.7 6.8 21.8
16 12 13.7 14.2 8.6 5.2 39.5in cases of high grade glioma in areas of functionally active
brain (Fig. 2).
4. Discussion
According to the classiﬁcation of the World Health
Organization (WHO), gliomas are of 3 main types astrocy-
tomas, oligodendrogliomas, and mixed oligoastrocytomas
which can usually be distinguished by their histologic features.
These tumors are typically heterogeneous in that different
levels of malignant degeneration can occur in different regions
within the same tumor. Analysis of the most malignant region
of the tumors establishes grading: low-grade, or WHO grades I
and II, and high-grade, or WHO grades III and IV. Grading is
based on the degree of nuclear atypia, mitosis, microvascular
proliferation, and necrosis, with increasing anaplasia as tumor
grade increases. The histologic features of the tumor and the
age and performance status of the patient are major prognostic
factors on outcome (7).
Several studies have explored the usefulness of dual time
point F-18 FDG positron emission tomography imaging
(DTPI) in improving detection of brain metastases and tumors
outside the brain, distinguishing malignant from benign lesions
or distinguishing malignant from inﬂammatory lesions (8).
Several investigations of delayed or DTPI F-18 FDG
PET of tumors have focused on measurements of SUV or
tumor-to-non tumor ratios and have shown that F-18 FDG
uptake does not plateau until well after the duration of standard
F-18 FDG PET studies (60 min after administration of F-18
FDG) (9). Spence et al. (6) had reported that F-18 FDG uptake
of a malignant brain lesion was gradually increased until
180 min after administration.As a result,DTPImay showbetter
performance to grade of brain tumors. F-18 FDGPET is a tech-
nique that permits measurement of regional cerebral glucose
metabolism. It provides a unique opportunity for the study of
physiological processes and is useful in the differentiation of
low-grade and high-grade gliomas (10). However Kaschtenat early and late time points; ratio of lesion/GM SUVmax; and
and histopathological grading.
GM
)
L/GM Diﬀerence L/GM
over time (%)
PET CT
grading
Pathological
grading
Early Late
1.21 1.48 22.5 Low Low
0.91 0.89 1.6 Low High
2.07 3.51 69.1 High High
0.56 0.56 20.5 Low Low
0.77 0.80 3.6 Low Low
1.40 2.63 88.8 High High
0.45 0.51 13.6 High Low
0.82 1.34 63.0 High High
0.87 1.03 18.9 Low Low
1.29 2.08 60.5 Low Low
2.18 3.49 59.7 High High
2.30 3.31 43.9 High High
1.01 1.32 30.4 High High
0.65 0.69 5.5 Low Low
0.68 0.91 34.4 High High
1.40 2.63 88.8 High High
Fig. 2 43 years old patient with right parietal high grade glioma by noncontrast CT (a), early (b) and late (c) PET images showed, early
SUVmax of the lesion was 16.8 and 22.8 in the late scan, difference of 35.7%, the GM early SUVmax was 8.1 and 6.5 in the late scan,
difference of about 19.8%, and the ratio between the lesion and gray matter uptake was 2.07 in the early and 3.51 in the late phase with
L/GM difference of 69.1%.
704 A.F.A. Ghany, M.A.G. Hamedet al. (11) and Sasaki et al. (12) reported that F-18 FDG uptake
did not allow differentiation between grade III and grade IV
gliomas.
Cutoff values for tumor-to-normal brain ratios have been
proposed by different authors, but the methodology and refer-
ences must be analyzed carefully. For prediction of prognosis
inside high-grade gliomas, Patronas et al. (13) used a cutoff
value of 1.4 for FDG tumor to contralateral region ratio,
but their results are not transposable because most of their
45 cases were recurrences. Delbeke et al. (14), on 58 untreated
gliomas studied with FDG, found that optimal cutoff value for
differentiation between low- and high-grade gliomas was 0.6
for tumor-to-fronto-parietal cortex ratio and 1.5 for the
T/WM ratio. No cutoff level was proposed between Grades
III and IV gliomas.
It is clear that increasing 18F-FDG-avid lesion SUVmax
values, decreasing background SUVmax values, and increasing
lesion-to background SUVmax ratio, support the potential
utility of delayed phase and dual-time-point diagnostic 18F
FDG PET/CT imaging. This suggests that delayed scans per-
formed at an appropriately selected extended injection to-scan
acquisition times can potentially minimize or alleviate the issue
of overlap in the pattern of 18F-FDG uptake between benign
tissues versus malignant tissues, as well as between background
tissues versus malignant tissues. However, further investiga-
tions are warranted to better assess this phenomenon and to
formally evaluate the clinical usefulness of extended injec-
tion-to-scan acquisition time intervals in various diagnostic
18F-FDG PET/CT oncologic imaging applications (15).
Di Chiro and coworkers (16) pioneered the application of
FDG-PET to gliomas. High-grade gliomas contained regions
of high FDG uptake and lower grade gliomas lacked these
regions. Patients with grade III or IV astrocytic gliomas tumor
uptake of FDG greater than the cortex were associated with a
median survival of about 10 months (17). More recently,
Padma et al. (18) reported 331 cases assessed by tumor/refer-
ence region ratios: 0 = no uptake, 1 6 normal white matter(WM), 2 normal WM< lesion < normal cortex, and
3P normal cortex. In categories 0 and 1 combined, 86% of
the tumors were grade I or II by pathology grading, with a
median survival of 2.3 years. In categories II and III combined,
94% were grade III or IV, with a median survival of
11 months.
Whereas several factors inﬂuencing survival have been iden-
tiﬁed in patients with high-grade astrocytoma, the prognostic
factors in adult low-grade gliomas remain poorly deﬁned
(19). Therefore, management of low-grade gliomas is still a
subject of controversy. Low-grade gliomas may present histo-
logical features of benign tumor but 20–25% per year undergo
malignant transformation. Low-grade gliomas may show his-
tological features of a benign tumor, but it is well known that
this may not be reﬂected in their long-term clinical course. The
5 year survival has been reported to range from 15% to 62%.
The average survival ranges between 23 and 63 months. These
ﬁgures vary with tumor location, patient’s age, surgical inter-
vention and radiotherapy. The natural history of a low-grade
glioma is not predictable from the histological picture in an
individual case. Muller et al. (20) studied 137 recurrent
low-grade gliomas and found that of grade I tumors, 56%
progressed to grade II and 31% to GBM over a period of
5 years. It has been shown that increased FDG uptake in his-
tologically proven low-grade glioma predicts in most cases a
deleterious evolution. This metabolic feature, detectable with a
non-invasive procedure, may provide a clue to cellular changes
announcing malignant transformation in a tumor which keeps
histological features of a low-grade glioma (17). Such data
indicate that PET may help in the stratiﬁcation of patients
entered in protocols which evaluate therapeutic strategies in
brain tumors. In high-grade gliomas, Barker et al. (21) studied
the prognostic value of FDG PET in 55 patients with malig-
nant glioma. In univariate analysis, the FDG PET score was
a signiﬁcant predictor of survival time after FDG PET scan-
ning (P= 0.005). Median survival was 10 months for patients
with FDG PET high uptake scores of 2 or 3 and 20 months for
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tional hazards analysis the FDG PET score was a signiﬁcant
predictor of survival (P= 0.019) in a model that included
patient’s age and FDG PET.
Our study results correlated with the results done by
Delbeke et al. that showed sensitivity of 94% and speciﬁcity
of 77% of dual phase PET CT in grading of gliomas, while
Kim et al. showed good correlation between dual phase PET
CT grading and histological grading of gliomas with
P< 0.035 compared to P< 0.003 in our study; however,
our statistics identiﬁed the L/GM ratio as the most accurate
parameter correlated with pathological results for grading of
glioma. Kim et al. showed that SUVmax in the delayed images
is the best parameter for grading, while Delbeke et al. showed
that Cutoff levels of 1.5 for the T/WM FDG uptake ratio and
0.6 for the T/C ratio are useful in the differentiation of
low-grade from high-grade gliomas with PET, and these differ-
ences could be attributed to low number of cases studied as
well as the small low group glioma patients.
Our study had some limitations, the study population was
small, and no correlation with other imaging modalities and
large prospective investigations are needed to support our
data.
In conclusion dual phase FDG PET CT has been proved to
be a reliable predictor of the proliferative activity of gliomas
when compared to histopathological classiﬁcation and can be
used for preoperative grading and as a prognostic factor of
gliomas.
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